Thrivory is betting that medical practices will pay a fee to never worry about denied claims again
On a typical Tuesday afternoon, an infusion clinic in suburban New Jersey submits a $15,000 claim for a specialty drug treatment. Under normal circumstances, the clinic waits. And waits. Fifty-seven days on average, according to industry benchmarks—sometimes longer if the insurer denies the claim and triggers an appeals process that can stretch for months.
Thrivory, a three-year-old healthcare fintech, wants to collapse that entire cycle into a few hours.
The Oradell-based startup closed a $3.5 million seed round on November 18, led by Redesign Health, the venture studio that originally incubated the company. Combined with a $3.96 million venture debt facility from Trinity Capital that closed in September, Thrivory now has roughly $28.5 million in total capital across three funding rounds, according to CBInsights data.
The premise is deceptively simple: Submit a claim through Thrivory's system, and the company will advance up to 80% of the expected reimbursement amount that same day. If the insurer later denies or delays payment, Thrivory absorbs the loss. The provider keeps the money either way—a non-recourse arrangement that essentially transfers all downstream risk to the fintech.
The Denial Problem
For independent practices and specialty clinics, the appeal is obvious. Denial rates on in-network claims reached 20% for some Affordable Care Act marketplace plans in 2023, according to data from KFF highlighted by Axios. Reworking a single rejected claim costs between $25 and $118 in administrative overhead, industry estimates suggest. Multiply that across dozens or hundreds of claims each month, and the friction adds up quickly.
Thrivory claims its AI models—trained on what the company describes as more than 40 billion historical claims—can predict denial risk and reimbursement amounts with 96% to 98% accuracy. That confidence is what allows the startup to front cash on claims filed with Medicare, Medicaid, and major commercial payers including Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealthcare.
Whether those accuracy figures hold at scale, and across every specialty and payer mix, remains to be seen. But the company is betting that its data science edge will prove durable enough to justify taking on the risk that most providers would rather avoid.
Embedded, Not Direct
Thrivory isn't trying to sell directly to every solo practitioner or small clinic scattered across the country. Instead, the company built ThriveNow, an API designed to plug into the practice management systems, revenue cycle management platforms, and fintech apps that providers already use daily.
The workflow is relatively straightforward: A practice submits claim data and a bank token through an integrated partner. Thrivory's models run a real-time adjudication prediction, and if approved, funding hits the practice's account the same day. When the payer eventually deposits the full reimbursement, reconciliation happens automatically in the background.
It's a distribution strategy borrowed from other vertical fintech players—embed where your customers already work, rather than fight for attention in a saturated market. Thrivory has inked partnerships with revenue cycle firms like IRR and Independent Recovery Resources, specialty providers like Allied Infusion, and payment platforms such as Nsure. Each partnership theoretically opens access to dozens or hundreds of practices without requiring individual sales cycles.
Leadership Shuffles and New Faces
Devon Seitz, Thrivory's current CEO, previously led engineering and data at the company. Patrick LaVoie, a co-founder, served as CEO through mid-2024 before stepping aside. In July 2024, the company added Wolfgang Koester as chairman—a fintech veteran who founded FiREapps and held roles at Kyriba. The leadership reshuffle suggests the company may be shifting from a product-build phase to a scaling phase, though Thrivory hasn't publicly detailed the reasons behind the transition.
Redesign Health, which raised a $175 million fund in December 2024 to spin out more healthcare tech companies, remains a strategic backer. The studio's continued involvement signals confidence, though venture studios often maintain close ties to their portfolio companies longer than traditional VCs might.
What Comes Next
The fresh capital will fund additional API integrations and expansion into new specialty verticals, the company says. Which specialties exactly—orthopedics, dermatology, behavioral health—Thrivory hasn't specified. But infusion therapy, with its high-cost specialty drugs and thin operating margins, appears to be an early focus.
The underlying bet is this: Enough practices will trade a transaction fee for immediate cash and zero denial risk that the embedded model scales faster than direct sales ever could. If Thrivory's AI models hold up under real-world pressure, the company could carve out a meaningful niche in a healthcare payments market that's historically been slow to innovate.
If the models falter, or if claim denial patterns shift in ways the algorithms didn't anticipate, the company could find itself shouldering losses it didn't price in. That's the double-edged nature of non-recourse financing—someone has to absorb the downside. Thrivory is wagering it can predict that downside more accurately than anyone else.
For now, the pitch is resonating enough to keep the funding flowing. Whether it scales remains the more interesting question.
